Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: A meta-analysis

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Kong, Yuan ^a   Wang, Dongping ^a   Shang, Yushu ^a   Liang, Wenhua ^a   Ling, Xiaoting ^a   Guo, Zhiyong ^a   He, Xiaoshun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; CALCINEURIN; CYCLOSPORIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ARTICLE; CLINICAL PROTOCOL; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; INFECTION; KIDNEY FAILURE; LIVER TRANSPLANTATION; META ANALYSIS; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; SYSTEMATIC REVIEW; COMMUNICABLE DISEASE; DRUG ANTAGONISM; FEMALE; INCIDENCE; KIDNEY; KIDNEY FUNCTION TEST; MALE; METABOLISM; PATHOPHYSIOLOGY; TIME;

CALCINEURIN; COMMUNICABLE DISEASES; CYCLOSPORINE; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; INCIDENCE; KIDNEY; KIDNEY FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TACROLIMUS; TIME FACTORS;

EID: 80052554884     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024387     Document Type: Article

References (60)

1. Organ Procurement and Transplant Network Available: http://optn.transplant.hrsa.gov/LatestData/viewDataReports.asp via the Internet. Accessed June 2011.
2. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, et al. (2003) Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349: 931-940.
3. Lebron Gallardo M, Herrera Gutierrez ME, Seller Perez G, Curiel Balsera E, Fernandez Ortega JF, et al. (2004) Risk factors for renal dysfunction in the postoperative course of liver transplant. Liver Transpl 11: 1379-1385.
4. Pawarode A, Fine DM, Thuluwath PJ, (2003) Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 9: 741-747.
5. Moreno JM, Cuervas-Mons V, Rubio E, Pons F, Herreros de TA, et al. (2003) Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transplant Proc 35: 1907-1908.
6. Campbell KM, Yazigi N, Ryckman FC, Alonso M, Tiao G, et al. (2006) High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation. J Pediatr 148: 475-480.
7. Cantarovich M, (2004) Renal dysfunction in liver transplantation: the problem and preventive strategies. Can J Gastroenterol 18 (suppl C): 27C-40C.
8. Johnson DW, Saunders HJ, Johnson FJ, Huq SO, Field MJ, et al. (1999) Fibrogenic effects of cyclosporin A on the tubulointerstitium: role of cytokines and growth factors. Exp Nephrol 7: 470-478.
9. Johnson DW, Saunders HJ, Johnson FJ, Huq SO, Field MJ, et al. (1999) Cyclosporin exerts a direct fibrogenic effect on human tubulointerstitial cells: roles of insulin-like growth factor I, transforming growth factor beta1, and platelet-derived growth factor. J Pharmacol Exp Ther 289: 535-542.
10. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M, (1984) Cyclosporine-associated chronic nephropathy. N Engl J Med 311: 699-705.
11. Jain A, Vekatramanan R, Eghtesad B, (2005) Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation 80: 859-864.
12. Kornberg A, Kupper B, Hommann M, Scheele J, (2005) Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction. Int Immunopharmacol 5: 141-146.
13. Cantarovich M, Tzimas GN, Barkun J, Deschenes M, Alpert E, et al. (2003) Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation 76: 98-102.
14. Schlitt HJ, Barkmann A, Boeker KHW, Schmidt HH, Emmanouilidis N, et al. (2001) Replacement of calcineurin inhibitors with mycophenolate mofetil in liver transplant patients with renal dysfunction: a randomized controlled study. Lancet 357: 587-591.
15. Simone PD, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, et al. (2009) Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 15: 1262-1269.
16. Cicinnati VR, Yu Z, Klein CG, Sotiropoulos GC, Saner F, et al. (2007) Clinical Trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients- assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol 26: 1195-1208.
17. Beckebaum S, Cicinnati VR, Klein CG, Brokalaki E, Yu Z, et al. (2004) Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. Transplant Proc 36: 2671-2674.
18. Pageaux GP, Rostaing L, Calmus Y, Duvoux C, Vanlemmens C, et al. (2006) Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 12: 1755-1760.
19. Eisenberger U, Sollinger D, Stickel F, Burckhardt B, Frey FJ, (2009) Relationship between renal resistance index and renal function in liver transplant recipients after cessation of calcineurin inhibitor. Clin Transplant 23: 499-504.
20. Rogers CC, Johnson SR, Mandelbrot DA, Pavlakis M, Horwedel T, et al. (2009) Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients. Clin Transplant 23: 887-896.
21. Biselli M, Vitale G, Gramenzi A, Riili A, Berardi S, et al. (2009) Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant. Clin Transplant 23: 191-198.
22. Shenoy S, Hardinger KL, Crippin J, Desai N, Korenblat K, et al. (2007) Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. Transplantation 83: 1389-1392.
23. Beckebaum S, Klein CG, Stiropoulos GC, Saner FH, Gerken G, et al. (2009) Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: clinical results of a prospective randomized study. Transplantation Proc 41: 2567-2569.
24. Pulido LB, Alamo Martinez JM, Pareja Ciuro F, Gomez Bravo MA, Serrano Diez-Canedo J, et al. (2008) Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors. Transplantation Proc 40: 2985-2987.
25. Reich DJ, Clavien PA, Hodge EE, (2005) Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation 80: 18-25.
26. Benedetto FD, Sandro SD, Ruvo ND, Montalti R, Guerrini GP, et al. (2009) Immunosuppressive switch to sirolimus in renal dysfunction after liver transplantation. Transplantations Pro 41: 1297-1299.
27. Ponton C, Vizcaino L, Tome S, Otero E, Molina E, et al. (2010) Improvement of renal function after conversion to mycophenolate mofetil combine with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction. Transplant Proc 42: 656-659.
28. Creput C, Blandin F, Deroure B, Roche B, Saliba F, et al. (2007) Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. Liver Transpl 13: 1004-1010.
29. Koch RO, Graziadei IW, Schulz F, Nachbaur K, Konigsrainer A, et al. (2004) Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl Int 17: 518-524.
30. Raimondo ML, Dagher L, Papatheodoridis GV, Rolando N, Patch DW, et al. (2003) Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 75: 186-190.
31. Planas JMM, Martinez VCM, Gonzalez ER, Cruz AG, Lopez-Monclus J, et al. (2004) Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 4: 1650-1655.
32. Tannuri U, Gibelli NEM, Maksoud-Filho JG, Santos MM, Pinho-Apezzato ML, et al. (2007) Mycophenolate mofetil promotes prolonged improvement of renal dysfunction after pediatric liver transplantation: experience of a single center. Pediatr Transpl 11: 82-86.
33. Pfitzmann R, Klupp J, Langrehr JM, Neuhaus R, Junge G, et al. (2002) Mycophenolate mofetil reduces calcineurin inhibitor-induced side effects after liver transplantation. Transplant Proc 34: 2936-2937.
34. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ, (2003) Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 9: 1079-1085.
35. Sanchez EQ, Martin AP, Ikegami T, Uemura T, Narasimhan G, et al. (2005) Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate. Transplant Proc 37: 4416-4423.
36. Yang YJ, Chen DZ, Li LX, Kou JT, Lang R, et al. (2008) Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency. Transplant Proc 40: 1541-1544.
37. Orlando G, Balocchi L, Cardillo A, Laria G, Liguori ND, et al. (2007) Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 13: 46-54.
38. Simone PD, Precisi A, Petruccelli S, Balzano E, Carrai P, et al. (2009) The impact of everolimus on renal function in maintenance liver transplantation. Transplant Proc 41: 1300-1302.
39. Dharancy S, Iannelli A, Hulin A, Declerck N, Schneck AS, et al. (2009) Mycophenolate mofetil monotherapy for severe side effects of calcineurin inhibitors following liver transplantation. Am J Transplant 9: 610-613.
40. Morard I, Dumortier J, Spahr L, Hadengue A, Majno P, et al. (2007) Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 13: 658-664.
41. Vivarelli M, Dazzi A, Cucchetti A, Gasbarrini A, Zanello M, et al. (2010) Sirolimus in liver transplant recipients: a large single-center experience. Transplantation Proc 42: 2579-2584.
42. Castroagudin J, Molina E, Varo E, (2011) Proteinuria predicts unfavourable evolution after switching of immunosuppression from calcineurin-inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Journal of Hepatology 54: S209-S361.
43. Cotterell AH, Fisher RA, King Al, Gehr TWB, Dawson S, et al. (2002) Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 16 (Suppl 7): 49-51.
44. Campistol JM, Sacks SH, (2000) Mechanisms of nephrotoxicity. Transplantation 69: SS5.
45. Lopez MM, Valenzuela JE, Alvarez FC, Lopez-Alvarez MR, Cecilia GS, et al. (2006) Long-term problems related to immunosuppression. Transplant Immunology 17: 31-35.
46. Manzia TM, De Liguori Carino N, Oriando G, Toti L, De Luca L, et al. (2005) Use of mycophenolate mofetil in liver transplantation: a literature review. Transplantation Proc 37: 2616-2617.
47. Stewart SF, Hudson M, Talbot D, Manas D, Day CP, (2001) Mycophenolate mofetil monotherapy in liver transplantation. Lancet 357: 609-610.
48. Moreno Planas JM, Cuervas-Mons MV, Rubio GE, (2004) Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 4: 1650-1655.
49. Fairbanks KD, Thuluvath PJ, (2004) Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl 10: 1189-1194.
50. Pierini A, Mirabella S, Brunati A, Ricchiuti A, Franchello A, et al. (2005) Mycophenolate mofetil monotherapy in liver transplantation. Transplant Proc 37: 2614-2615.
51. McAlister VC, Peltekian KM, Malatjalian DA, Colohan S, MacDonald S, et al. (2001) Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 7: 701-708.
52. Watson CJ, Friend PJ, Jamieson NV, Frick TW, Alexander G, et al. (1999) Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 67: 505-509.
53. Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, et al. (2000) Experience with the use of sirolimus in liver transplantation- use in patients for whom CNIs are contraindicated. Liver Transpl 6: 734-740.
54. Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, et al. (2001) Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol The 69: 48-56.
55. Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, et al. (2006) Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 12: 1640-1648.
56. Watson CJE, Gimson AES, Alexander GJ, Allison MED, Gibbs P, et al. (2007) A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 13: 1694-1702.
57. Lam P, Yoshida A, Brown K, Abouljoud M, Bajjoka I, et al. (2004) The efficacy and limitations of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. Digestive Diseases and Sciences 49: 1029-1035.
58. Vivarelli M, Cucchetti A, Barba GL, Ravaioli M, Del Gaudio M, et al. (2008) Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 248: 857-862.
59. Panwalkar A, Verstovsek S, Giles FJ, (2004) Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100: 657-666.
60. Guba M, Von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128-135.